Secretagogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
== WADA proscription == In 2015, Radwa Arafa Abd Elsalam, an athlete from Egypt, underwent a doping control where ractopamine was identified in the sample. Elsalam was sanctioned by the Egyptian Anti-Doping Organisation (EGY-NADO) with a two year ineligibility period for non-intentional presence of a prohibited substance, in violation of Article 2.1 of the EGY-NADO rules. While not mentioned by name in the 2015 Prohibited List, ractopamine was determined to — much like clenbuterol, another β2-adrenergic agonist — constitute an Other Anabolic Agent prohibited under S1.2. Elsalam appealed the decision, claiming that ractopamine is used in the meat industry overseas, so she must have inadvertently consumed food contaminated with ractopamine. EGY-NADO accepted her appeal, reduced the sanction to six months, and provided the World Anti-Doping Agency (WADA) with records pertaining to the case. WADA filed an appeal with the Court of Arbitration for Sport (CAS) against EGY-NADO and Elsalam with respect to the appealed decision. WADA asserted ractopamine was "undisputed[ly]" an Other Anabolic Agent, that "[i]t is not sufficient for an athlete merely to make protestations of innocence and suggest that the prohibited substance must have entered her body in inadvertently", and that "her explanations are nothing more than mere speculation".
=== 15 May === During President Zelenskyy's surprise visit to Paris, a joint statement from him and President Emmanuel Macron said that France would train and equip the Ukrainian military with tens of armoured vehicles and light tanks including the AMX-10RC. It also said that France would support Ukraine's air defence capacities and increase sanctions on Russia. Visiting the United Kingdom later that day, Zelenskyy was promised hundreds of air defence missiles, as well as "long-range attack drones" with a range of more than 200 km (120 mi) by Prime Minister Rishi Sunak. The Governor of Kharkiv Oblast said two civilians were killed by Russian shelling in Dvorichna. Russia also shelled the town of Vovchansk, damaging three residential buildings, farm buildings and a hospital, while four buildings where damaged in Tsyschchenkova. Four people were killed in a Russian missile attack on a hospital in Avdiivka, Donetsk Oblast. Russia claimed to have shot down a British-supplied Storm Shadow missile for the first time as well as 10 HIMARS MLRS shells. Igor Kornet, the acting interior minister of the Russian-backed Luhansk People's Republic, was reported to have been injured in an explosion at a barbershop in Luhansk city along with six other people. Four of the injured, including Kornet, were said to be in a "serious condition". President Vladimir Putin signed a decree that simplified the process for its foreign volunteers in Ukraine to gain Russian citizenship and extended its eligibility to include their spouses, children and parents.
== Description == Calvatia gigantea grows up to 10–50 centimetres (4–19+1⁄2 in) wide and high. It can grow to 80 cm diameter and weigh several kilograms. A specimen weighing over 23 kg (51 lb) was recorded in Thunder Bay, Ontario, Canada. The interior of an immature puffball is white, while that of a mature specimen is greenish brown. The fruiting body of a puffball mushroom develops within a few weeks and soon begins to decompose and rot, at which point it becomes dangerous to eat. Unlike most mushrooms, all the spores of the giant puffball are created inside the fruiting body; large specimens can easily contain several trillion. The spores are yellowish, smooth, and 3–6 μm in size. They produce a white spore print when young, while it is olive with an unpleasant smell in age. Prof. John Lindley has calculated that C. gigantea grows at a rate of sixty million new cells per minute on its way to making seven quintillion (7 × 1018) spores.
==== Crystallinity ==== When applied to polymers, the term crystalline has a somewhat ambiguous usage. In some cases, the term crystalline finds identical usage to that used in conventional crystallography. For example, the structure of a crystalline protein or polynucleotide, such as a sample prepared for x-ray crystallography, may be defined in terms of a conventional unit cell composed of one or more polymer molecules with cell dimensions of hundreds of angstroms or more. A synthetic polymer may be loosely described as crystalline if it contains regions of three-dimensional ordering on atomic (rather than macromolecular) length scales, usually arising from intramolecular folding or stacking of adjacent chains. Synthetic polymers may consist of both crystalline and amorphous regions; the degree of crystallinity may be expressed in terms of a weight fraction or volume fraction of crystalline material. Few synthetic polymers are entirely crystalline. The crystallinity of polymers is characterized by their degree of crystallinity, ranging from zero for a completely non-crystalline polymer to one for a theoretical completely crystalline polymer. Polymers with microcrystalline regions are generally tougher (can be bent more without breaking) and more impact-resistant than totally amorphous polymers. Polymers with a degree of crystallinity approaching zero or one will tend to be transparent, while polymers with intermediate degrees of crystallinity will tend to be opaque due to light scattering by crystalline or glassy regions.
On 13 May 1983, two peat workers at Lindow Moss, Andy Mould and Stephen Dooley, noticed an unusual object—about the size of a football—on the elevator taking peat to the shredding machine. They removed the object for closer inspection, joking that it was a dinosaur egg. Once the peat had been removed, their discovery turned out to be a decomposing, incomplete human head with one eye and some hair intact. Forensics identified the skull as belonging to a European woman, probably aged 30–50. Police initially thought the skull was that of Malika Reyn-Bardt, who had disappeared in 1960 and was the subject of an ongoing investigation. While in prison on another charge, her husband, Peter Reyn-Bardt, had boasted that he had killed his wife and buried her in the back garden of their bungalow, which was on the edge of the area of mossland where peat was being dug. The garden had been examined but no body was found. When Reyn-Bardt was confronted with the discovery of the skull from Lindow Moss, he confessed to the murder of his wife. The skull was later radiocarbon dated, revealing it to be nearly 2,000 years old. "Lindow Woman", as it became known, dated from around 210 AD. This emerged shortly before Reyn-Bardt went to trial, but he was convicted on the evidence of his confession.
Sources: en.wikipedia.org
A religion-focused conception of well-being is also found in the Islamic tradition and the teachings of the Quran, which asserts that material pleasures are temporary and that genuine well-being depends on religious faith and complete dedication to Allah.
The Nobel Prize committee in 1923 credited the practical extraction of insulin to a team at the University of Toronto and awarded the Nobel Prize to two men: Frederick Banting and John Macleod. They were awarded the Nobel Prize in Physiology or Medicine in 1923 for the discovery of insulin. Banting, incensed that Best was not mentioned, shared his prize with him, and Macleod immediately shared his with James Collip. The patent for insulin was sold to the University of Toronto for one dollar. Two other Nobel Prizes have been awarded for work on insulin. British molecular biologist Frederick Sanger, who determined the primary structure of insulin in 1955, was awarded the 1958 Nobel Prize in Chemistry. Rosalyn Sussman Yalow received the 1977 Nobel Prize in Medicine for the development of the radioimmunoassay for insulin. Several Nobel Prizes also have an indirect connection with insulin. George Minot, co-recipient of the 1934 Nobel Prize for the development of the first effective treatment for pernicious anemia, had diabetes. William Castle observed that the 1921 discovery of insulin, arriving in time to keep Minot alive, was therefore also responsible for the discovery of a cure for pernicious anemia. Dorothy Hodgkin was awarded a Nobel Prize in Chemistry in 1964 for the development of crystallography, the technique she used for deciphering the complete molecular structure of insulin in 1969.
The cultivation of opium [in Afghanistan] reached its peak in 1999, when 350 square miles (910 km2) of poppies were sown ... The following year the Taliban banned poppy cultivation, ... a move which cut production by 94 percent ... By 2001 only 30 square miles (78 km2) of land were in use for growing opium poppies. A year later, after American and British troops had removed the Taliban and installed the interim government, the land under cultivation leapt back to 285 square miles (740 km2), with Afghanistan supplanting Burma to become the world's largest opium producer once more. Opium production in that country has increased rapidly since, reaching an all-time high in 2006. War in Afghanistan once again appeared as a facilitator of the trade. Some 3.3 million Afghans are involved in producing opium.
=== Biosynthesis === α-Bungarotoxin is a peptide, therefore it undergoes the protein synthesis pathway, involving transcription and translation. The specific genes encoding for the protein are transcribed into mRNA, which is then translated via the ribosomes, leading to the synthesis of the prepropeptide. Lastly, post-translational modification and folding occur. The mature peptide is stored in the venom gland until envenomation when it gets released.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.